Digestive side effects of approved and upcoming GLP-1 and dual GIP/GLP-1 receptor medicines, including oral forms

Gastrointestinal (GI) adverse events are the most common limitation of glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists.

• GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are significant advancements in treating type 2 diabetes and obesity.
• GI adverse events frequently lead to discontinuation of these therapies.
• The prevalence of GI issues suggests a need for better management strategies for patients using these treatments.

Simplified